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Abstract
Dupuytren's contracture (DC) is the most common inherited connective tissue disease of humans
and is hypothesized to be associated with aberrant wound healing of the palmar fascia. Fibroblasts
and myofibroblasts are believed to play an important role in the genesis of DC and the
fibroproliferation and contraction that are hallmarks of this disease. This study compares the gene
expression profiles of fibroblasts isolated from DC patients and controls in an attempt to identify
key genes whose regulation might be significantly altered in fibroblasts found within the palmar
fascia of Dupuytren's patients. Total RNA isolated from diseased palmar fascia (DC) and normal
palmar fascia (obtained during carpal tunnel release; 6 samples per group) was subjected to
quantitative analyses using two different microarray platforms (GE Code Link™ and Illumina™) to
identify and validate differentially expressed genes. The data obtained was analyzed using The
Significance Analysis of Microarrays (SAM) software through which we identified 69 and 40
differentially regulated gene transcripts using the CodeLink™ and Illumina™ platforms,
respectively. The CodeLink™ platform identified 18 upregulated and 51 downregulated genes.
Using the Illumina™ platform, 40 genes were identified as downregulated, eleven of which were
identified by both platforms. Quantitative RT-PCR confirmed the downregulation of three high-
interest candidate genes which are all components of the extracellular matrix: proteoglycan 4
(PRG4), fibulin-1 (FBLN-1) transcript variant D, and type XV collagen alpha 1 chain. Overall, our
study has identified a variety of candidate genes that may be involved in the pathophysiology of
Dupuytren's contracture and may ultimately serve as attractive molecular targets for alternative
therapies.
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Dupuytren's contracture (DC) is the most common inher-
ited disease of connective tissue in humans [1] and an
autosomal dominant form of the disease was recently
mapped to the long arm of chromosome 16 [2]. The dis-
ease is characterized by the appearance of small nodules
of hyperproliferative cells within the palmar fascia that,
over time, give rise to large bands of contracted, collagen-
rich fibrotic tissue (diseased cords), a hallmark of the dis-
ease [3,4]. If left untreated, this disease may impose severe
limitations on hand function. It is a familial disorder that
is highly prevalent in individuals of Northern European
extraction [5,6] and is observed less frequently among
other ethnicities [7]. The manifestations of Dupuytren's
are usually noticeable between the ages of 40 to 60 and
with a higher incidence in men than in women [8].
Although the pathogenesis of DC disease has not been
fully explained it is clear that genetics plays an important
role; traumatic factors may also be important and may
explain the male gender bias of the disease. In addition, a
number of metabolic conditions that negatively affect
wound healing processes in general have been statistically
associated with DC including: diabetes mellitus (8%),
alcoholism (10%), smoking, and HIV infection [9-12].
Finally, there is a puzzling connection with epilepsy (2%).
The mainstay of treatment is surgery, but no specific sur-
gical approach has proved to be consistently more effec-
tive than others at curing this condition as the trauma
associated with surgery itself can lead to recurrence. Possi-
ble alternatives to surgery include injection of steroids, γ-
interferon [13,14], use of creams based on vitamin E,
dimethylsulphoxides, drugs inducing hypo-uricaemia,
ultrasonic therapy [15] and clostridial collagenase injec-
tion [16]. However, these medical treatments appear to be
either temporary alternatives to surgical intervention with
only limited success at best, or are still under clinical
assessment.
Previous studies have identified dysregulation among
multiple structural proteins in DC, including: type I and
type III collagens; the extracellular matrix (ECM) proteins
fibronectin, tenascin C, and laminin; as well as matrix
metalloproteinases in the diseased fascial cords [17,18].
Previous studies have also shown that a number of signal-
ing molecules such as transforming growth factor β
(TGFβ), epidermal growth factor (EGF) and platelet
derived growth factor (PDGF) are differentially regulated
in DC [19,20]. No specific causative gene has yet been
identified and identification of susceptibility loci may
help to unravel the pathogenesis of this common disease.
Our laboratory has investigated the pattern of inheritance
of DC in a large Swedish family and has shown that DC is
inherited as an autosomal dominant disorder with incom-
plete penetrance by the end of the fifth decade [2]. A
genome-wide scan at a resolution of ~8 cM for all auto-
somes established linkage to a single 6 cM region between
markers D16S419 and D16S3032 on chromosome 16q.
In contrast, Bayat et al., (2005) [21] identified a hetero-
plasmic mitochondrial mutation associated with DC.
These investigators have also identified associations
between polymorphisms in the human TGFβRI and Zf9
genes with DC [22,23] raising the possibility that DC may
be the common result of multiple disparate genetic
lesions.
Previously investigators have conducted differential gene
expression profiling of tissues collected from Dupuytren's
patients (using normal palmar fascia as controls [24-26]).
In the present study we compare the gene expression pat-
terns in fibroblasts derived from DC and carpal tunnel
patients, as fibroblasts are believed to play an important
role in the genesis of DC and fibroproliferation is one of
the hallmarks of the disorder [27,28]. Since DC has been
hypothesized to result from an impaired wound healing
response, cellular elements such as myofibroblasts (pri-
marily derived from fibroblasts), which are implicated
both in the contraction of wound granulation tissue and
the scar-like disease cords that define DC, are attractive
targets for study. Fibroblasts/myofibroblasts actively con-
trol both extracellular matrix remodeling and scar deposi-
tion; processes which are central to wound healing and
may be dysregulated in DC. In this context, the present
study was designed as an attempt to identify key genes
whose expression is significantly altered in the principal
cell type of interest during the development of
Dupuytren's contracture. We have followed the recom-
mendations of the Microarray Quality Control Consor-
tium (MAQC) [29], which recommends the use of
multiple microarray platforms for the quantitative charac-
terization of gene expression. Accordingly, we used both




Dupuytren's contracture cords were surgically resected at
St Joseph's Hospital and normal palmar fascia was
obtained from patients undergoing carpal tunnel release
within the Hand and Upper Limb Centre (HULC) clinic,
London, Ontario, Canada. Primary fibroblasts were iso-
lated from freshly surgically resected DC cord or carpal
tunnel resection-derived normal palmar fascia explants in
starter medium containing α-MEM-medium (Invitrogen
Corporation, Carlsbad, CA) supplemented with 10% fetal
bovine serum (Gemini Bioproducts, West Sacramento,
CA) and 1% antibiotic-antimycotic solution (Sigma-
Aldrich, St Louis, MO) in the Cell and Molecular Biology
Laboratory of the HULC. Fibroblasts were identified byPage 2 of 12
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were grown in 10 cm2 plates and, upon reaching 80% con-
fluence, were lysed using RLT-lysis buffer to extract total
RNA (Qiagen, Valencia, CA). RNA quality was assessed by
ODA260/280 using an ND-1000 spectrophotometer (Nano-
drop Technologies Inc, Wilmington, DE) and by capillary
electrophoresis with the Agilent 2100 bioanalyzer (Agi-
lent Technolgies, Inc. Santa Clara, CA). All subjects pro-
vided written informed consent under the approval of the
Health Sciences Research Involving Human Subjects
(HSREB) and specimens were collected in strict compli-
ance by the physician performing the surgeries.
Micorarray Expression Analyses using Illumina™ and GE 
CodeLink™ Bioarray Systems
Microarray experiments were performed to identify genes
that are differentially expressed in fibroblasts derived
from DC-affected palmar fascia versus those derived from
normal fascia. 500 ng samples of total RNA, isolated from
palmar fascia fibroblasts, derived either from carpal tun-
nel release (CTR) controls (N = 6) or DC-affected patients
(N = 6), were subjected to analyses with the CodeLink™
Human Whole Genome Bioarray System (containing
~57,000 transcript probes which includes ~45,000 well
characterized transcript targets, GE Healthcare Biosciences
Corp; Piscataway, NJ) and the Sentrix Human-6 Expres-
sion Beadchip (which contains more than 48,000 tran-
script probes, Illumina; SanDiego, CA). Total RNA was
amplified, labeled and hybridized according to the manu-
facturers' protocols. Biotin labeled cRNA probe was pre-
pared by a linear amplification method. After first and
second strand synthesis, the cDNA served as the template
for an in vitro transcription (IVT) reaction to produce the
target cRNA. The biotin labeled cRNA (10 µg for Code-
Link™ and 1.5 µg for Illumina™) was hybridized overnight
in a temperature controlled shaking incubator at 37°C.
Post-hybridization processing included a stringent wash
to remove unbound and non-specifically hybridized tar-
get molecules, a staining step with a Cy™ 5-streptavidin
conjugate (CodeLink™) or with Cy™3-streptavidin conju-
gate (Illumina™) followed by several non-stringent wash-
ing steps to remove unbound conjugate. Following a final
rinse, the bioarrays were dried by centrifugation and
scanned. The CodeLink bioarrays were read in a Lumonix-
Packard scanner and the Illumina arrays were read in an
Illumina Bead Array Reader. The data from both platforms
were analyzed using the Significance Analysis of Microar-
rays (SAM) software package [30].
Analysis of Gene Expression Data
SAM software tool v3.0 was applied to identify those
genes that had statistically significant differences in
expression between Dupuytren's- and carpal tunnel-
derived fibroblasts [30]. Briefly, SAM computes a score for
each gene that measures the strength of transcript correla-
tion with differential expression. A threshold value of 1.03
and 1.17 was chosen for CodeLink™ and Illimina™ data
respectively, as estimated by repeatedly permuting the sur-
vival times and counting the number of genes that were
significant at each threshold. Missing data were handled
using the K-nearest neighbors imputer (k = 2) of the SAM
imputation gene.
Network Generation and Functional Analysis Using 
Ingenuity Pathways Analysis
Network and functional analyses were generated through
the use of Ingenuity Pathways Analysis (Ingenuity Sys-
tems). A data set containing gene identifiers and corre-
sponding expression values was uploaded into the
application. Each gene identifier was mapped to its corre-
sponding gene object in the Ingenuity Pathways Knowl-
edge Base. These genes, called Focus Genes, were overlaid
onto a global molecular network developed from infor-
mation contained in the Ingenuity Pathways Knowledge
Base. Networks of these Focus Genes were then algorith-
mically generated based on their connectivity. The Func-
tional Analysis of a network identified the biological
functions and/or diseases that were most significant to the
genes in the network. Fischer's exact test was used to cal-
culate a p value determining the probability that each bio-
logical function and/or disease assigned to that network is
due to chance alone. A p value ≤ 0.05 was considered sig-
nificant. Canonical pathways analysis of the Ingenuity
Pathways Analysis Library identified those pathways that
were most significant to the data set.
Real-time RT-PCR
Real-time RT-PCR-based assays were performed for three
gene products of interest whose annotation suggested a
plausible role in the pathogenesis of DC. These included:
proteoglycan 4 (PRG4), fibulin 1 – transcript variant D,
and type XV collagen. For these assays, total RNA was iso-
lated from normal and diseased palmar fascia fibroblasts
using the RNeasy Micro Kit (Qiagen Inc. USA, Valencia,
CA). Reverse transcription was performed using 10 ng of
total RNA with M-MLV-reverse transcriptase (In Vitrogen
Corporation, Carlsbad, CA) with random primers at a
concentration of 100 ng/µl. GAPDH was simultaneously
assayed by quantitative RT-PCR as an endogenous invari-
ant control for normalization. PCR amplification and
detection of template was carried out using Applied Bio-
systems transcript-specific assays including: proteoglycan
4 – Hs00195140_m1, type XV collagen –
Hs01559630_m1, fibulin 1 (transcript variant D) –
Hs00197774_m1. These assay kits utilize FAM™Taqman®
MGB probes and a Taqman® Universal PCR Master Mix, all
obtained from Applied Biosystems (Foster City, CA). Each
reaction mix contained template cDNA at a concentration
of 15 ng/µl, and 20× final concentration of Gene Expres-
sion Mix which contains both forward and reverse primersPage 3 of 12
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ume of 15.0 µl. Following reaction setup, aliquots were
transferred into a microAMP Optical 96-well reaction
plate (Applied Biosystems). Samples were vortexed,
briefly centrifuged, and sealed with an optical adhesive
cover (Applied Biosystems). The universal thermal cycling
protocol suggested by the Applied Biosystems protocol
was performed using the ABI Prism ® 7900 HT sequence
detection system using the following cycling conditions:
enzyme activation at 95°C for 10 minutes, followed by 40
cycles of two-temperature PCR at 95°C for 15 seconds and
60°C for 1 minute. Using the comparative critical cycle
(Ct) method the expression levels of the target genes were
normalized to the GAPDH endogenous control and the
relative abundance was calculated. Data were analyzed
using the 7900 HT SDS software version 2.1 provided by
Applied Biosystems.
Statistical Analysis
The real time RT-PCR data were analyzed using an
unpaired two-tailed Student's t test to determine the sta-
tistical significant difference in gene expression levels
between control and diseased fibroblasts. A p value ≤ 0.05
was considered significant.
Results
The present study was designed to identify differences in
the gene expression patterns between primary
Dupuytren's contracture-derived fibroblasts and primary
carpal tunnel-derived control fibroblasts. This was
achieved employing two different microarray platforms,
the GE CodeLink™ and Illumina™, using RNA extracted
from primary cultures of carpal tunnel- and DC-derived
fibroblasts within passages 2–5 of tissue culture (P2–P5).
Furthermore, several high interest candidate genes identi-
fied by analysis of the microarray data were further vali-
dated using quantitative real time RT-PCR, and the online
Ingenuity Knowledge Based Analysis system was used to
identify signaling pathways that could serve as potential
therapeutic targets to limit the recurrence of DC disease.
Microarray
SAM software (v3.0) [30] was applied to global median
normalized data from CodeLink™. The data from the Illu-
mina™ analysis was median normalized and background
values were subsequently removed in accordance with the
manufacturer's protocol before analysis using SAM. Genes
that were differentially expressed between the control and
diseased fibroblasts in at least four of six samples were
included in the analysis. The % coefficient of variation
(CVs) of the GE CodeLink ™ and Illumina ™ data were cal-
culated and the results were 16.9% and 17.74% for the
controls (carpal tunnel derived fibroblasts) and 17.1%
and 12.13% for the test samples (Dupuytren's contracture
cord derived fibroblasts) that were then analyzed using
SAM. This incorporated all 47,290 (GE CodeLink™) and
48,000 (Illumina™) transcript probes in the genome wide
arrays. Thus the two groups were comparable. A two-class
unpaired comparison of gene expression data with SAM
was performed at a false discovery rate (FDR %) of 8.1%
(Delta value of 1.03) with CodeLink™ data; for Illumina™
SAM was performed at a FDR % of 1.0% (Delta value of
1.17).
We identified 69 genes and ESTs that were differentially
expressed using the CodeLink™ arrays and 40 using the
Illumina™ arrays. Of the 69 CodeLink-identified genes, 18
were upregulated and 51 were downregulated (including
ESTs and cDNA clones of unknown function). All 40
genes and ESTs identified using the Illumina™ platform
were downregulated (Table 1, 2 &3). A comparison of the
data from the two platforms identified 11 genes that were
identified as being downregulated by both systems.
We also identified several other differentially expressed
genes of interest using the Illumina™ platform but not
CodeLink™ platform through SAM analysis. Interestingly,
direct examination of the CodeLink data set revealed that
these genes were also observed to be downregulated by
the CodeLink software (Table 4), albeit not sufficiently to
satisfy the extremely stringent parameters of SAM analysis.
Subsequent direct quantification of three genes by quanti-
tative RT-PCR confirmed their relative underexpression in
DC-derived fibroblasts, indicating that these data were
consistent.
Ingenuity Analysis
To annotate the sets of genes identified as differentially
expressed we used a web-based software, developed by
Ingenuity Pathways Analysis [IPA], which derives path-
ways that are significantly altered by comparing genes
identified by SAM against all genes from the CodeLink™
and Illumina™ arrays. Table 5 shows the molecules
involved in various networks and their primary functions
related to the networks. In Network 1, 14 focus genes were
associated with 12 additional genes by direct interactions,
which were primarily linked with cell death, neurological
disease and cancer. Twelve focus genes were directly
linked with 10 other genes in the Knowledge Database,
together composing Network 2, primarily associated with
cell death, gene expression and cancer. The 7 focus genes
linked with 4 other genes involved in Network 3 are asso-
ciated with dermatological diseases and conditions, cellu-
lar growth and proliferation. Networks 4 and 5 consisted
of 1 focus gene each but were involved in a wide variety of
functions including cardiovascular system development
and function, cellular compromise, cellular growth and
proliferation, lipid metabolism, nucleic acid metabolism
and small molecule biochemistry. Table 6 groups the
focus genes based on the cellular function/pathways orPage 4 of 12
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works 1, 2, 3, 4 and 5 also revealed tumor necrosis factor
(TNF), interferon gamma (IFN γ), mitogen-activated pro-
tein kinase 3 (MAPK3), DNA damage inducible transcript
4-like (DDIT4L) and pyruvate dehydrogenase kinase 3
(PDK3) to be the most outstanding partners found within
the network.
Gene Products Validated Using Real time RT-PCR
Real-time RT-PCR was used to confirm the expression lev-
els of three candidate genes: proteoglycan 4 (PRG4), fibu-
lin-1 (FBLN-1) transcript variant D and type XV collagen
alpha 1 chain (Figure 1, 2 &3). These genes were all iden-
tified as downregulated in the data sets of both microarray
based platforms (although SAM analysis picked them out
only in one). Real-time RT-PCR results showed that PRG4
mRNA levels in DC fibroblasts was less than 10% of that
in control fibroblasts. Similarly the FBLN-1 and collagen
genes showed expression levels of less than 40% of those
observed in the controls. Thus, in all three cases, the quan-
titative RT-PCR results confirmed the microarray findings.
Discussion
The microarray analyses of DC fibroblasts versus controls
reported here identified far more genes as downregulated
in the disease samples than upregulated. This is consistent
with previous microarray findings from DC tissues
wherein the authors similarly report substantially more
downregulated genes than upregulated genes [31],
although a countervailing report identified more genes as
upregulated than downregulated on tissues derived from
DC [24]. The present study using fibroblast cultures did
not identify some of the previously reported genes that
might be involved in DC, eg. alpha-1 integrins, MafB [25]
or various MMPs/TIMPS [26]. This may be due to differ-
ences between tissues (where multiple cell types may be
present, possibly interacting with each other) and cul-
tured cells expressing a solitary phenotype. Our results
across two microarray platforms are internally consistent
and indicate that fibroblast cell populations in DC gener-
ally preferentially downregulate selected gene expression
relative to control cells.
Dupuytren's disease presents two fibrotic structures that
are clearly identifiable: the nodule and the cord [32,4].
The nodule is a relatively vascular tissue containing a
dense population of fibroblasts, with a high proportion
being myofibroblasts. In contrast, the cord is a collagen-
rich structure that is relatively avascular and acellular, and
with a lesser (but still significant) abundance of myofi-
broblasts. The slow progression of the disease, combined
with a lack of awareness as to eventual severity and that
surgical resection is rarely performed in the absence of
pronounced finger contracture, limits the availability of
nodule tissue for experimental study.
In the present study, we identified by microarray analyses
candidate genes from cord-derived fibroblasts that might
serve as targets for intervention to limit the recurrence of
palmar fascia fibrosis. One of the hallmarks of DC is
Table 1: Genes upregulated in palmar fascia fibroblasts obtained from Dupuytren's Contracture using CodeLink™ platform. 
Gene ID Gene Name Fold Change
1. NM_014893 Neuroligin 4, Y-linked (NLGN4Y) 10.4
2. NM_004653 Jumonji, AT rich interactive domain 1D (RB2-like) (JARID1D) 9.4
3. NM_003411 Zinc finger protein, Y-linked (ZFY) 8.9
4. NM_138963 Ribosomal protein S4, Y-linked 2 (RPS4Y2) 6.7
5. NM_004660 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked (DDX3Y) 6.3
6. NM_001008 Ribosomal protein S4, Y-linked 1 (RPS4Y1) 6.1
7. NM_002527 Neurotrophin 3 (NTF3) 2.9
8. NM_006558 KH domain containing, RNA binding, signal transduction associated 3 (KHDRBS3) 1.8
9. NM_033546 Myosin regulatory light chain MRLC2 (MRLC2) 1.3
10. NM_198833 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8 (SERPINB8) 1.2
cDNA of Unknown Biological Function
1. AA156287 zo33b08s1 Stratagene colon (#937204) cDNA clone IMAGE:588663 3' 74.62
2. BQ924832 AGENCOURT_8840265 Lupski_sciatic_nerve cDNA clone IMAGE:6205036 5' 9.46
3. BX648643 mRNA; cDNA DKFZp686O17106 (from clone DKFZp686O17106) 8.13
4. Z48511 HSXGPEP11 H. sapiens XG mRNA (clone PEP11) 7.21
5. AI674196 wc09d11x1 NCI_CGAP_Pr28 cDNA clone IMAGE:2314677 3' 6.85
6. H70730 yu69e10r1 Weizmann Olfactory Epithelium cDNA clone IMAGE:239082 5' 5.76
7. AA49137 zx03d12r1 Soares_total_fetus_Nb2HF8_9w cDNA clone IMAGE:785399 5' 2.94
8. NM_032576 Chromosome Y open reading frame 15B (CYorf15B), mRNA 2.71
SAM analysis was performed to identify the statistically significant differentially expressed genes.Page 5 of 12
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Table 2: Genes downregulated in palmar fascia fibroblasts obtained from Dupuytren's Contracture using CodeLink™ Platform. 
Gene ID Gene Name Fold Change
1. NM_002847 Protein tyrosine phosphatase, receptor type, N polypeptide 2 (PTPRN2), transcript variant 1 0.16
2. NM_021602 CD79B antigen (immunoglobulin-associated beta) (CD79B), transcript variant 2 0.18
3. NM_001831 Clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate 
message 2, apolipoprotein J) (CLU), transcript variant 1
0.21
4. NM_004000 chitinase-3-like 2 (CHI3L2) 0.22
5. NM_152536 FYVE, RhoGEF and PH domain containing 5 (FGD5), mRNA 0.25
6. NM_000668 Alcohol dehydrogenase 1B (class I), beta polypeptide (ADH1B) 0.29
7. NM_001831 clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed 
prostate message 2, apolipoprotein J) (CLU), transcript variant 1
0.30
8. NM_005410 selenoprotein P, plasma, 1 (SEPP1) 0.34
9. NM_005525 hydroxysteroid (11-beta)dehydrogenase 1 (HSD11B1), transcript variant 1 0.35
10. NM_145244 DNA-damage inducible transcript 4-like (DDIT4L) 0.37
11. NM_012168 F-box protein 2 (FBXO2), mRNA 0.38
12. NM_021146 angiopoietin-like factor (CDT6) 0.39
13. U83115 Non-lens beta gamma-crystallin like protein (AIM1)mRNA 0.42
14. NM_001801 cysteine dioxygenase type1 (CDO1) 0.45
15. NM_005627 serum/glucocorticoid regulated kinase (SGK) 0.49
16. NM_002928 Regulator of G-protein signaling 16 (RGS16) 0.49
17. NM_000690 aldehyde dehydrogenase 2 family (mitochondrial) (ALDH2), nuclear gene encoding mitochondrial 
protein
0.54
18. NM_005391 pyruvate dehydrogenase kinase, isoenzyme 3 (PDK3) 0.55
19. NM_000636 superoxide dismutase 2, mitochondrial (SOD2) 0.56
20. NM_006391 Importin 7 (IPO7) 0.57
21. NM_030968 C1q and tumor necrosis factor related protein 1 (C1QTNF1), transcript variant 1 0.58
22. NM_001353 aldo-keto reductase family 1, member C1 (dihyrdodiol dehydrogenase 1;20-alpha (3-alpha)-
hydroxysteroid dehydrogenase) (AKR1C1)
0.59
cDNA of Unknown Biological Function
1. D52654 HUM084D02B Clontech human fetal brain polyA+ mRNA (#6535) cDNA clone GEN-084D02 5' 0.00
2. AI597810 tu91f07x1 NCI_CGAP_Gas4 cDNA clone IMAGE:2258437 3' similar to contains L1.t1 L1 L1 repetitive 
element;
0.01
3. H90897 yu89c07s1 Soares fetal liver spleen 1NFLS cDNA clone IMAGE:240972 3' 0.10
4. NM_021602 CD79B antigen (immunoglobulin-associated beta) (CD79B), transcript variant 2 0.18
5. BX094389 NCI_CGAP_Ut4 cDNA clone IMAGp998O234898 0.23
6. NM_152536 FYVE, RhoGEF and PH domain containing 5 (FGD5), mRNA 0.25
7. AK054990 cDNA FLJ30428 fis, clone BRACE2008941 0.31
8. AA866107 oh53b03.s1 NCI_CGAP_GC4 cDNA clone IMAGE:1470317 3' 0.33
9. BU624020 UI-H-FG1-bgh-h-24-0-UIs1 NCI_CGAP_FG1 cDNA clone UI-H-FG1-bgh-h-24-0-UI 3' 0.34
10. AI186220 qd34a02x1 Soares_fetal_heart_NbHH19W cDNA clone IMAGE:1731338 3' 0.35
11. BG117761 602350442F1 NIH_MGC_90 cDNA clone IMAGE:4445147 5' 0.40
12. BM929454 UI-E-EJ1-aje-b-23-0-UIr1 UI-E-EJ1 cDNA clone UI-E-EJ1-aje-b-23-0-UI 5' 0.42
13. AL117425 mRNA; cDNA DKFZp566L203 (from clone DKFZp566L203) 0.43
14. BQ430788 AGENCOURT_7776027 NIH_MGC_68 cDNA clone IMAGE:6024295 5' 0.44
15. AA594928 no40a05s1 NCI_CGAP_Pr23 cDNA clone IMAGE:1103120 3' 0.46
16. H05195 yl85f06r1 Soares infant brain 1NIB cDNA clone IMAGE:45005 5' 0.47
17. AK124841 cDNA FLJ42851 fis, clone BRHIP2005719 0.47
18. H05195 yl85f06r1 Soares infant brain 1NIB cDNA clone IMAGE:45005 5' 0.48
19. AL119769 DKFZp761E1224_r1 761 (synonym: hamy2) cDNA clone DKFZp761E1224 5' 0.54
20. AI094001 qa28a03s1 Soares_NhHMPu_S1 cDNA clone IMAGE:1688044 3' 0.54
21. AL133055 mRNA; cDNA DKFZp434J1015 (from clone DKFZp434J1015) 0.56
22. BX094154 Soares fetal liver spleen 1NFLS cDNA clone IMAGp998P17654 0.58
23. W67378 zd40b03r1 Soares_fetal_heart_NbHH19W cDNA clone IMAGE:343085 5' similar to SW:DHAM_HUMAN 
P05091 ALDEHYDE DEHYDROGENASE, MITOCHONDRIAL PRECURSOR;
0.58
24. BM829211 K-EST0102153 S9SNU601 cDNA clone S9SNU601-57-C10 5' 0.58
25. BM711907 UI-E-CL1-afc-i-20-0-UIr1 UI-E-CL1 cDNA clone UI-E-CL1-afc-i-20-0-UI 5' 0.59
26. BX088944 Soares_testis_NHT cDNA clone MAGp998J113516; IMAGE:1392490 0.72
27. BC033399 clone IMAGE:4829538 0.77
28. CB960582 AGENCOURT_13892014 NIH_MGC_147 cDNA clone IMAGE:30343321 5' 0.79
29. BC034566 clone IMAGE:4821877, mRNA 0.79
SAM analysis was performed to identify the statistically significant differentially expressed genes. Genes that are common to both platforms are 
highlighted as Bold and Italics.
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Table 3: Genes downregulated in palmar fascia fibroblasts obtained from Dupuytren's Contracture using Illumina™ Platform. 
Gene ID Gene Name Fold Change
1. NM_005807 Homo sapiens proteoglycan 4 (PRG4), mRNA. 0.08
2. NM_020299 Homo sapiens aldo-keto reductase family 1, member B10 aldose reductase) (AKR1B10), mRNA. 0.15
3. NM_145176 Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 12 (SLC2A12), mRNA. 0.18
4. NM_001831 clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed 
prostate message 2, apolipoprotein J) (CLU), transcript variant 1
0.21
5. NM_012168 F-box protein 2 (FBXO2), mRNA 0.21
6. NM_139125 Homo sapiens mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) 
(MASP1), transcript variant 2, mRNA.
0.22
7. NM_000691 Homo sapiens aldehyde dehydrogenase 3 family, memberA1 (ALDH3A1), mRNA 0.22
8. NM_178127 Homo sapiens angiopoietin-like 5 (ANGPTL5), mRNA 0.23
9. NM_004000 chitinase-3-like 2 (CHI3L2) 0.22
10. NM_005410 Homo sapiens selenoprotein P, plasma, 1 (SEPP1), mRNA 0.23
11. NM_001996 Homo sapiens fibulin 1 (FBLN1), transcript variant C, mRNA 0.24
12. NM_015714 Homo sapiens G0/G1switch 2 (G0S2), mRNA 0.24
13. NM_021146 angiopoietin-like factor (CDT6) 0.24
14. NM_006486 Homo sapiens fibulin 1 (FBLN1), transcript variant D, mRNA 0.25
15. NM_000956 Homo sapiens prostaglandin E receptor 2 (subtype EP2), 53kDa (PTGER2), mRNA 0.26
16. NM_005525 Homo sapiens hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), transcript variant 1, mRNA 0.28
17. NM_173640 Homo sapiens R-spondin homolog (Xenopus laevis) (RSPO1), transcript variant 2, mRNA. 0.30
18. NM_001801 cysteine dioxygenase type1 (CDO1) 0.30
19. XM_352750 Homo sapiens collagen, type XIV, alpha 1 (undulin) (COL14A1), mRNA. 0.31
20. NM_002150 Homo sapiens 4-hydroxyphenylpyruvate dioxygenase (HPD), mRNA 0.33
21. NM_001855 Homo sapiens collagen, type XV, alpha 1 (COL15A1), mRNA. 0.33
22. XM_166300 Homo sapiens absent in melanoma 1 (AIM1), mRNA 0.36
23. NM_005627 Homo sapiens serum/glucocorticoid regulated kinase (SGK), mRNA 0.36
24. NM_016564 Homo sapiens cell cycle exit and neuronal differentiation 1 (CEND1), mRNA. 0.38
25. NM_133371 Homo sapiens myozenin 3 (MYOZ3), mRNA 0.40
26. NM_001290 Homo sapiens LIM domain binding 2 (LDB2), mRNA. 0.41
27. NM_003383 Homo sapiens very low density lipoprotein receptor (VLDLR), transcript variant 1, mRNA. 0.43
28. NM_005631 Homo sapiens smoothened homolog (Drosophila) (SMO), mRNA 0.43
29. NM_014746 Homo sapiens ring finger protein 144 (RNF144), mRNA 0.44
30. NM_000636 superoxide dismutase 2, mitochondrial (SOD2) 0.45
31. NM_000690 aldehyde dehydrogenase 2 family (mitochondrial) (ALDH2), nuclear gene encoding mitochondrial 
protein, mRNA.
0.48
32. NM_002222 Homo sapiens inositol 1,4,5-triphosphate receptor, type 1 (ITPR1), mRNA 0.48
33. NM_012329 Homo sapiens monocyte to macrophage differentiation-associated (MMD), mRNA. 0.50
34. NM_000861 Homo sapiens histamine receptor H1 (HRH1), mRNA 0.50
35. NM_001353 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1;20-alpha (3-alpha)-
hydroxysteroid dehydrogenase) (AKR1C1)
0.51
cDNA of Unknown Biological Function
1. NM_024563.2 Homo sapiens chromosome 5 open reading frame 23 (c5orf23)mRNA 0.48
2. XM_376189.1 Homo sapiens DKFZP586K1520 protein (DKFZP586K1520), mRNA 0.41
3. NM_014859.1 Homo sapiens KIAA0672 gene product (KIAA0672), mRNA. 0.28
4. XM_352945.1 Homo sapiens hypothetical protein FLJ37034 (FLJ37034), mRNA 0.46
5. NM_138409.1 Homo sapiens chromosome 6 open reading frame 117 (C6orf117), mRNA 0.21
SAM analysis was performed to identify the statistically significant differentially expressed genes. Genes that are common to both platforms are 
highlighted as Bold and Italics.
Table 4: mRNA levels of gene products that are significantly different in CodeLink™ gene array platform similar to Illumina™ 
platform.
Gene Control Diseased Fold Change P value
1. NM_005807 Homo sapiens PRG4 791.69 60.72 0.15 0.01
2. NM_006486 Fibulin 1(FBLN1), transcript variant D 101.28 30.97 0.30 0.007
3. NM_001855 Collagen, Type XV, alpha 1 (COL15A1) 52.92 19.59 0.37 0.01
4. NM_000691 aldehyde dehydrogenase 3 family, member A1 12.02 3.89 0.32 0.006
BMC Medical Genomics 2008, 1:10 http://www.biomedcentral.com/1755-8794/1/10abnormal proliferation of fibroblasts [33,34] with exces-
sive production of collagen (predominantly type III colla-
gen) along with elevated levels of other ECM proteins,
mainly fibronectin, tenascin and laminin [17,35,36].
Higher expression of laminin and tenascin has been
reported in nodular tissues [35] and an elevated level of
fibronectin expression has been found in both nodular
tissues and in cord derived fibroblasts [36]. Since altera-
tions in ECM proteins appear to play an important role in
DC, we looked for differences in the gene expression pat-
terns of several ECM proteins between normal and dis-
eased derived palmar fascia fibroblasts. Intriguingly, we
did identify changes in the expression of other ECM pro-
teins including, types XIV and XV collagens, PRG4 and
FBLN1 transcript variant D which have not been previ-
ously associated with DC. The three fibroblast-derived
ECM genes were initially identified through SAM analysis
of the Illumina™ data, but were not identified by SAM
using the CodeLink™ data. However, direct inspection of
the CodeLink raw data did show a statistically significant
downregulation of these genes that was confirmed by real-
time RT-PCR analysis (Table 4 & Figure 1, 2 &3).
Milani et al., (1994) [37] reported that type XV collagen
(undulin) is constitutively expressed in normal hepatic
liver, but that its levels are elevated in fibrotic liver, sug-
gesting its participation in the rearrangement of connec-
tive tissue during fibrotic disease. Since DC is a
fibroproliferative disease, high levels of undulin might be
expected. Our analysis however, indicates that type XV
collagen mRNA levels are relatively lower in Dupuytren's-
derived fibroblasts, suggesting that overexpression of this
gene product is not universal in fibrotic disorders but may
vary with tissue type and location. The downregulation of
type XV collagen in DC-derived fibroblasts warrants fur-
ther study as it has been shown previously that lack of type
XV collagen results in skeletal myopathy and cardiovascu-
lar defects in mice, demonstrating that type XV collagen
can prove a significant contributor in the pathogenesis of
musculoskeletal disorders [38].
We also identified two other ECM proteins, PRG4 and
FBLN1, as being downregulated in DC-derived fibrob-
lasts. PRG4, also commonly referred to as megakaryocyte
stimulating factor, articular superficial zone protein and
lubricin, is a multifaceted cytoprotective glycoprotein that
independently or additively contributes to boundary
lubrication in synovial joints and at articular cartilage-car-
tilage interfaces [39,40]. Recently Alazami et al., (2006)
[41] have corroborated the earlier findings of Marcelino et
al., (1999) [42] demonstrating that camptodactyly-
arthropathy-coxavara-pericarditis (CACP) syndrome
(where one or more fingers are curved inwards on the
palm (flexed) and cannot be straightened) is an auto-
somal recessive disorder caused by mutations in the PRG4
gene. Moreover, PRG4 deficiency has also been implicated
in the pathogenesis of osteoarthritis [43], thus making
this an attractive candidate gene for further study. The
Table 5: Ingenuity analysis comprised of five networks on the genes differentially identified using SAM analysis.
Networks Associated Network Functions Score Focus Genes Top Functions
1 AKR1C1, ALDH2, ALDH3A2, CD79B, CLU, FBLN1, 
GOS2, HSD11B1, IPO7, LAMA4, NPTX2, SERPINB8, 
SOD2, WTAP
26 14 Cell Death, Neurological Disease and Cancer
2 ADH1B, AIM1, CDO1, CHI3L2, FBXO2, JUP, 
KHDRBS3, PLA2G1B, PTPRN2, SEPP1, SMAD1, 
SMCY
12 12 Cell Death, Gene Expression, Cancer
3 COL14A1, MRLC2, MAGPA, NTF3, RGS16, RHOF, 
SGK
7 7 Dermatological Diseases and Conditions, Cellular 
Growth and Proliferation
4 DDIT4L 1 1 Cardiovascular System Development and 
Function, Cellular Compromise, Cellular Growth 
and Proliferation
5 PDK3 1 1 Lipid Metabolism, Nucleic Acid Metabolism, Small 
Molecule Biochemistry
Table 6: Top canonical pathways identified by ingenuity knowledge based analysis in Dupuytren's Contracture.
Function Significance (p value) Genes
Bile Acid Biosynthesis 4.96E-04 ADH1B, ALDH2, ALDH3A2
Ascorbate and Aldarate Metabolism 1.11E-03 ALDH2, ALDH3A2
Glycolipid Metabolism 4.8E-03 ADH1B, ALDH2, ALDH3A2
Glycolysis/Gluconeogenesis 6.41E-03 ADH1B, ALDH2, ALDH3A2
Histidine Metabolism 9.42E-03 ALDH2, ALDH3A2Page 8 of 12
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:10 http://www.biomedcentral.com/1755-8794/1/10fibulin-1 gene, which encodes both an extracellular matrix
protein and a secreted plasma glycoprotein, has been
found to be disrupted in a chromosomal translocation
(12;22) which results in haploinsufficiency for the
FBLN1-D variant in synpolydactyly, a congenital condi-
tion characterized by a union of fingers or toes and/or
increase in the number of toes or fingers. Biochemical
analyses of synpolydactyly fibroblasts showed signifi-
cantly reduced levels of FBLN1-D polypeptide incorpo-
rated in the ECM [44]. In summary, PRG4, fibulin-1 and
type XV collagen are all potential candidates for being
involved in the pathogenesis of DC and the biological role
of these ECM proteins in this disease warrants further
study. Interestingly, Ingenuity Knowledge Based Analysis
identified fibulin-1 as a focus gene; it is one of the many
genes included in Network 1 and appears to have interac-
tion with other ECM proteins, namely laminin 4, versican
(chondritin sulfate proteoglycan 2) along with the tran-
scription factor Sp1 (SP1) and connective tissue growth
factor (CTGF).
In addition to the genes discussed above, we identified
several others that produced concordant results on the
two microarray platforms. These included three metabolic
genes involved in alcohol metabolism: aldehyde dehydro-
genase 2 family (ALDH2), aldo-keto reductase family,
member C1 (AKR1C1), aldehyde dehydrogenase 3 fam-
ily, member A1 (ALDH3A1), all of which were downreg-
ulated in the DC palmar fascia fibroblasts relative to
controls and observed previously by Pan et al. (2003)
[31]. ALDH2 was identified as a focus gene and listed as a
target in various signaling cascades (Table 6) through
Ingenuity Knowledge Based Analysis. The analysis also
suggests that TNF might increase the expression of
ALDH2. The data provides further evidence that these
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BMC Medical Genomics 2008, 1:10 http://www.biomedcentral.com/1755-8794/1/10metabolic genes have the potential to play a role in the
progression of DC. In our studies, ALDH2 and AKR1C1
were identified by both platforms, whereas ALDH3A1 was
not identified by the CodeLink™ platform. However, a
close examination of the data points for ALDH3A1 in the
CodeLink™ data set does reveal a statistically significant
reduction (p < 0.005) with greater than a 3-fold change
between the two study groups (Table 4), albeit not
enough to satisfy the extremely stringent parameters of
SAM analysis. The downregulation of these three genes
involved in alcohol metabolism is congruent with the
observation that alcohol consumption is linked with
Dupuytren's disease.
There is also some evidence to show that a relationship
exists between the pathogenesis of Dupuytren's contrac-
ture induced by various oxidative stress molecules, includ-
ing superoxide radical (O2-), hydrogen peroxide (H2O2)
and the hydroxyl radical (OH-) [45,46]. It is hypothesized
that the progressive restriction of capillaries with age,
smoking and other environmental factors leads to a con-
dition of localized hypoxia resulting in increased levels of
xanthine oxidase and the subsequent production of free
radicals. In the present study, we found mitochondrial
superoxide dismutase 2, cysteine dioxygenase type 1, and
selenoprotein P, plasma, 1 (SEPP1) to be downregulated
in DC-derived fibroblasts. Low levels of these enzymes
may render DC-derived fibroblasts deficient in their abil-
ity to detoxify superoxide radicals or to oxidize cysteine
residues as an antioxidant defense mechanism [45,47].
Clusterin, a secreted mammalian chaperone associated
with stress-associated cell survival (anti-apoptotic gene)
[48] is also downregulated in DC, contrasting with its
overexpression in several human cancers such as prostate,
breast, and squamous cell carcinoma [49,50].
Chitinase-3-like 2 (CHI3L2), a secreted glycoprotein com-
ponent of the ECM which has been linked to early detec-
tion and prognosis of ovarian cancer, was identified in
this study. CHI3L2 appears to be downregulated in DC as
opposed to increased expression seen in ovarian cancer
patients [51]. Angiopoietin-like factor (CDT6), a homo-
logue to the angiopoietin gene family, is a glycoprotein
that is involved in vascular morphogenesis and mainte-
nance through binding to the vascular endothelial Tie2
receptor [52]. CDT6 is also found to be downregulated in
DC-derived fibroblasts. The significance of altered
CHI3L2 and CDT6 expression to the progression of
Dupuytren's contracture is as yet unclear.
The finding that serum/glucocorticoid regulated kinase
(SGK) message is downregulated in DC fibroblasts is con-
trary to previous studies that document a high level of
expression of SGK transcript in fibrosing disorders such as
Crohn's disease, fibrosing pancreatitis, diabetic nephrop-
athy, lung fibrosis and liver scirrhosis [53]. F-box protein
2 (FBXO2), which plays a crucial factor in the ubiquitin-
mediated degradation of cellular regulatory proteins [54],
is also noted to be downregulated in DC-derived fibrob-
lasts. Hydroxysteroid (11-beta) dehydrogenase transcript
variant 1 catalyzes the interconversion of biologically
inactive glucocorticoid (cortisone) to active glucocorti-
coid (cortisol); it has been shown to play a predominant
role in obesity, type 2 diabetes [55] and hypertension but
its role in fibrotic disease is yet to be determined.
Of interest is the observation that 29 of the dysregulated
genes identified in the DC fibroblasts are of unknown
function, suggesting that entirely new pathways may be
operational here that have not been previously character-
ized. An understanding of these genes and their protein
products may provide new insights into DC and other dis-
orders potentially associated with DC. In summary, our
study reveals a variety of candidate genes, some of known
function, some of unknown function, that together with
additional genetic studies will point the way to a better
understanding of this most common of human connec-
tive tissue disorders.
Conclusion
The present study using fibroblasts derived from DC
patients has identified a variety of candidate genes that
may be involved in the pathophysiology of palmar fibro-
sis which may ultimately serve as attractive molecular tar-
gets for alternative therapies. Future studies will further
correlate the changes in the mRNA levels to the protein
expression both at the cellular and tissue level which will
provide further clues to intervene and limit the progres-
sion/recurrence of DC.
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